Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL

AACR 2020

27 - 28 Apr 2020

Published: 30 Jun 2020

Views: 761

Rating:

Save

Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA

Dr Haneen Shalabi speaks to ecancer in an online interview for the virtual AACR 2020 meeting.

She discusses the results of the phase 1 dose-escalation study evaluating the safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL.

Dr Shalabi goes through the background to the study and talks us through the methodology used.

She reports that the CAR T cells were well tolerated at all dose levels with a reversible side effect profile and patients did respond.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

$Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )$

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in...

Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )

More from ecancer